Cargando…

A 60-Year-Old Woman with Primary Biliary Cholangitis and Crohn’s Ileitis Following the Suspension of Ursodeoxycholic Acid

Patient: Female, 60-year-old Final Diagnosis: Cholangitis • Crohn’s disease Symptoms: Asthenia • diarrhea • pruritus Medication: — Clinical Procedure: Endoscopy • MRI Specialty: Gastroenterology and Hepatology OBJECTIVE: Unusual clinical course BACKGROUND: There is a recognized association between i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Romeo, Mario, Cipullo, Marina, Iadanza, Giorgia, Olivieri, Simone, Gravina, Antonietta Gerarda, Pellegrino, Raffaele, Panarese, Iacopo, Dallio, Marcello, Federico, Alessandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Scientific Literature, Inc. 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9608254/ https://www.ncbi.nlm.nih.gov/pubmed/36273261 http://dx.doi.org/10.12659/AJCR.936387

Ejemplares similares

Predictive Model of Ursodeoxycholic Acid Treatment Response in Primary Biliary Cholangitis
por: Shu, Yanyun, et al.
Publicado: (2021)

Quality of bowel preparation in patients with inflammatory bowel disease undergoing colonoscopy: What factors to consider?
por: Gravina, Antonietta Gerarda, et al.
Publicado: (2023)

External validation of the United Kingdom‐primary biliary cholangitis risk scores of patients with primary biliary cholangitis treated with ursodeoxycholic acid
por: Cheung, Angela C., et al.
Publicado: (2018)

Fibrates for the Treatment of Primary Biliary Cholangitis Unresponsive to Ursodeoxycholic Acid: An Exploratory Study
por: Cançado, Guilherme Grossi Lopes, et al.
Publicado: (2022)

Evaluation of the United Kingdom‐primary biliary cholangitis and global primary biliary cholangitis group prognostic models for primary biliary cholangitis patients treated with ursodeoxycholic acid in the U.S. population
por: Alomari, Mohammad, et al.
Publicado: (2019)

Crohn's ileitis and salpingo-oophoritis.
por: Allen, D. C., et al.
Publicado: (1995)

Regional Ileitis (Crohn's Disease)
Publicado: (1943)

Looking Into the Crystal Ball: Predicting Non-response to Ursodeoxycholic Acid in Primary Biliary Cholangitis
por: Zimmer, Vincent, et al.
Publicado: (2016)

Terminal ileitis is not always Crohn’s disease
por: Bojic, Daniela, et al.
Publicado: (2011)

Bacterial and metabolic phenotypes associated with inadequate response to ursodeoxycholic acid treatment in primary biliary cholangitis
por: Martinez-Gili, Laura, et al.
Publicado: (2023)

Combination therapy of obeticholic acid and ursodeoxycholic acid in patients with primary biliary cholangitis who respond incompletely to ursodeoxycholic acid: a systematic review
por: Li, Xuan, et al.
Publicado: (2020)

Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis
por: Harms, Maren H, et al.
Publicado: (2020)

Combination therapy of ursodeoxycholic acid and glucocorticoid and (or) immunosuppressant in patients with primary biliary cholangitis: A meta-analysis
por: Wang, Zi-Long, et al.
Publicado: (2022)

A randomized, controlled trial on fenofibrate in primary biliary cholangitis patients with incomplete response to ursodeoxycholic acid
por: Li, Chunlei, et al.
Publicado: (2022)

T.08.5 THE OVERALL SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) PANDEMIC IMPACT ON METABOLIC (DYSFUNCTION) ASSOCIATED FATTY LIVER DISEASE. A PRELIMINARY EVALUATION
por: Romeo, M., et al.
Publicado: (2022)

Effectiveness of bezafibrate and ursodeoxycholic acid in patients with primary biliary cholangitis: a meta-analysis of randomized controlled trials
por: Agrawal, Rohit, et al.
Publicado: (2019)

Efficacy and safety of fenofibrate addition therapy in patients with cirrhotic primary biliary cholangitis with incomplete response to ursodeoxycholic acid
por: Ding, Dawei, et al.
Publicado: (2022)

Prediction and evaluation of high-risk patients with primary biliary cholangitis receiving ursodeoxycholic acid therapy: an early criterion
por: Yang, Chunmei, et al.
Publicado: (2022)

Efficacy of ursodeoxycholic acid for primary biliary cholangitis: Experience from a tertiary care centre in Saudi Arabia
por: AlWabel, Ahmed H, et al.
Publicado: (2022)

Irreversible metronidazole encephalopathy in an elderly woman with primary biliary cholangitis
por: Onuma, Yuki, et al.
Publicado: (2017)

SHIP deficiency causes Crohn's disease-like ileitis
por: Kerr, William G, et al.
Publicado: (2010)

Facing Terminal Ileitis: Going Beyond Crohn’s Disease
por: Goulart, Ricardo de Alvares, et al.
Publicado: (2016)

Isotretinoin-Induced Distal Ileitis Mimicking Crohn’s Disease
por: Pereira-Nunes, Joana, et al.
Publicado: (2023)

Late onset crohns ileitis—A diagnostic dilemma
por: Sunder, Ashok, et al.
Publicado: (2022)

Concomitant Sjögren's Syndrome Was Not Associated with a Poorer Response or Outcomes in Ursodeoxycholic Acid-Treated Patients with Primary Biliary Cholangitis
por: Ni, Ping, et al.
Publicado: (2019)

Predictors for incomplete response to ursodeoxycholic acid in primary biliary cholangitis. Data from a national registry of liver disease
por: Cortez‐Pinto, Helena, et al.
Publicado: (2021)

Treatment of ursodeoxycholic acid with glucocorticoids and immunosuppressants may improve the long-term survival rate in primary biliary cholangitis patients
por: Wang, Zi-Long, et al.
Publicado: (2022)

Dietary Creatine as a Possible Novel Treatment for Crohn’s Ileitis
por: Roy, Abhik, et al.
Publicado: (2016)

Ursodeoxycholate inhibits mast cell activation and reverses biliary injury and fibrosis in Mdr2(−/−) mice and human primary sclerosing cholangitis
por: Meng, Fanyin, et al.
Publicado: (2018)

Prognostic Factors for Transplant-Free Survival and Validation of Prognostic Models in Chinese Patients with Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid
por: Cheung, Ka-Shing, et al.
Publicado: (2017)

Ursodeoxycholic Acid at 18–22 mg/kg/d Showed a Promising Capacity for Treating Refractory Primary Biliary Cholangitis
por: Xiang, Xinyu, et al.
Publicado: (2021)

Liver transplant‐free survival according to alkaline phosphatase and GLOBE score in patients with primary biliary cholangitis treated with ursodeoxycholic acid
por: de Veer, Rozanne C., et al.
Publicado: (2022)

Ursodeoxycholic Acid Treatment–Induced GLOBE Score Changes Are Associated With Liver Transplantation-Free Survival in Patients With Primary Biliary Cholangitis
por: de Veer, Rozanne C., et al.
Publicado: (2023)

Clinical Outcomes and Validation of Ursodeoxycholic Acid Response Scores in Patients with Korean Primary Biliary Cholangitis: A Multicenter Cohort Study
por: Chang, Jong-In, et al.
Publicado: (2023)

Adherence and Effects Derived from FODMAP Diet on Irritable Bowel Syndrome: A Real Life Evaluation of a Large Follow-Up Observation
por: Gravina, Antonietta Gerarda, et al.
Publicado: (2020)

Editorial: Challenges in Inflammatory Bowel Disease: Current, Future and Unmet Needs
por: Gravina, Antonietta Gerarda, et al.
Publicado: (2022)

Editorial: Challenges in inflammatory bowel disease: current, future and unmet needs, volume II
por: Gravina, Antonietta Gerarda, et al.
Publicado: (2023)

High neutrophil-lymphocyte ratio indicates a worse response to ursodeoxycholic acid in primary biliary cholangitis: a retrospective cohort study
por: Zhu, Huiling, et al.
Publicado: (2023)

Host and microbiota interactions are critical for development of murine Crohn's-like ileitis
por: Roulis, M, et al.
Publicado: (2015)

Tuberculosis terminal ileitis: A forgotten entity mimicking Crohn’s disease
por: Gurzu, Simona, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_bs45270q922p9i04bjtapvk8h1